Mechanisms Underlying Predictors of Success From Obesity Surgery

• Status: Active, not recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this project is to identify predictors of success in the treatment of obesity after bariatric surgery. The specific aims of this proposal are to:

1. Employ behavioral tests of mechanisms that control food intake in normal weight individuals, to determine which intake control mechanisms lead to changes after Roux-en-y gastric bypass (RYGB) or sleeve gastrectomy (SG); and

2. Measure behavioral and psycho-social predictors of weight loss and food intake reduction, so as to determine which are most predictive of successful weight loss and food intake reduction.

3. Account for success in reduction of food intake brought about by the pattern of hormone release, particularly glucagon-like peptide-1 (GLP-1), Peptide YY (PYY) and gastric distention, known to underlie satiation, coupled with post-ingestive changes in reinforcing value of food and motivation to consume.

Tests of the hypothesis will be done by measuring responses to tasting, working for, and consuming, foods on sensory, motivational, cognitive, and physiological variables, including amount consumed and rate of eating under standardized conditions, before surgery and at a two year follow up visit. In addition, the inhibitor sitagliptin will be administered the night before and day of test meal and exendin-9-39 (EX9) will be infused before and during the meal to determine whether blockade of GLP-1 / PYY receptors after surgery reverses intake reduction. Investigators predict that successful patients will show changes that favor reduction in food intake, rate of eating, motivation to consume, reward value of foods, and a hormone profile that has been shown to generate satiation and maintain reduction in intake (e.g. increased Cholecystokinin (CCK), GLP-1, PYY, reduced ghrelin). To the extent that psycho-social and cognitive factors may override physiological brakes to eating behavior, the subjects may fail to achieve success, and consequently the failure may be predicted from over-impulsiveness or inability to suppress working for rewarding food stimuli. To test these hypotheses, a total of 83 patients will be enrolled prior to RYGB/SG and restudied 2 years after the surgery. The sitagliptin / EX9 studies will be done in a subset of 32 completers. To test this aim, patients will be divided into 4 groups of 19. The 4 patients from each group with the most weight loss (% weight loss ≥35 at 2 years post-surgery, 16 patients in total) and least weight loss (% weight loss of ≤25 at two years 16 patients in total) will be recruited for these two additional post-operative visits within one year of completing Visit #3 after the RYGB/SG surgery. A total of 32 patients will be recruited for visits 4 and 5.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University; Icahn School of Medicine at Mount Sinai
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• BMI >35 kg/m2 BMI

• BMI < 65 kg/m2

• Preparing to undergo Roux-en-Y gastric bypass or gastric sleeve (RYGB/GS) surgery at St. Luke-Roosevelt Hospital

• Within the 18-65 age range

• Blood pressure under <160/100 mmHg

• Fasting triglyceride <600 mg/dl

• No recent (last 6 months) history of cardiovascular disease.

• Prior history of angioplasty or coronary artery bypass surgery with a normal stress test will not be a contraindication.

Exclusion Criteria:

• Diabetes Mellitus

• Active cancer

• Unstable angina

• Recent stroke

• Current therapy that may affect glucose metabolism such as glucocorticoids, adrenergic agents

• Active infection

• Kidney failure

• Severe liver dysfunction

• Heavy alcohol use

• Severe respiratory or cardiac failure

• Pancreatitis

• History of bullous pemphigoid

• Pregnancy

• Patients who are currently or have had prior GLP-1 therapy.

• Patients with known hypersensitivity to Exendin 9-39 or similar products, albumin, sitagliptin and/or acetaminophen will also be excluded.

Additional exclusions for visits 4 and 5 ONLY:

• Patients at risk for heart disease, such as patients with a history of atherosclerotic cardiovascular disease and history of heart failure

• Renal impairment (eGFR˂60 Ml/MIN/1.73 M2)

• History of exfoliative skin conditions in particularly if occurring with a DPP-4 inhibitor use

• History of bullous pemphigoid and Stevens-Johnson syndrome.